1. Home
  2. KD vs GRFS Comparison

KD vs GRFS Comparison

Compare KD & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$24.86

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.66

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KD
GRFS
Founded
2020
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
6.2B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
KD
GRFS
Price
$24.86
$8.66
Analyst Decision
Buy
Hold
Analyst Count
5
2
Target Price
$39.60
$10.15
AVG Volume (30 Days)
2.0M
485.7K
Earning Date
02-04-2026
07-28-2022
Dividend Yield
N/A
1.60%
EPS Growth
N/A
N/A
EPS
1.68
0.64
Revenue
$15,008,000,000.00
$8,821,017,248.00
Revenue This Year
$6.40
$5.36
Revenue Next Year
$3.60
$5.15
P/E Ratio
$15.01
$17.13
Revenue Growth
N/A
7.31
52 Week Low
$23.28
$6.19
52 Week High
$44.20
$11.14

Technical Indicators

Market Signals
Indicator
KD
GRFS
Relative Strength Index (RSI) 34.40 40.06
Support Level $26.79 $8.79
Resistance Level $27.68 $9.40
Average True Range (ATR) 0.86 0.23
MACD -0.19 -0.07
Stochastic Oscillator 9.55 3.19

Price Performance

Historical Comparison
KD
GRFS

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: